Samuel Weiss

Summary

Affiliation: University of Calgary
Country: Canada

Publications

  1. Illes J, Weiss S, Bains J, Chandler J, Conrod P, De Koninck Y, et al. A Neuroethics Backbone for the Evolving Canadian Brain Research Strategy. Neuron. 2019;101:370-374 pubmed publisher
  2. Chesnelong C, Restall I, Weiss S. Isolation and Culture of Glioblastoma Brain Tumor Stem Cells. Methods Mol Biol. 2019;1869:11-21 pubmed publisher
    ..In this chapter, we describe a method to isolate and culture these BTSCs from fresh GBM patient samples. ..
  3. Luchman H, Stechishin O, Nguyen S, Lun X, Cairncross J, Weiss S. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival. Clin Cancer Res. 2014;20:5756-67 pubmed publisher
    ..AZD8055 was synergistic with the alkylating agent TMZ and significantly prolonged animal survival. These data suggest that dual inhibition of mTORC1/2 may be of benefit in GBM, including the subset of TMZ-resistant GBMs. ..
  4. Zhornitsky S, Johnson T, Metz L, Weiss S, Yong V. Prolactin in combination with interferon-β reduces disease severity in an animal model of multiple sclerosis. J Neuroinflammation. 2015;12:55 pubmed publisher
    ..Histological analyses corroborated the clinical EAE data. These results suggest that prolactin may be beneficial when administered in combination with interferon-β in MS. ..
  5. Cusulin C, Chesnelong C, Bose P, Bilenky M, Kopciuk K, Chan J, et al. Precursor States of Brain Tumor Initiating Cell Lines Are Predictive of Survival in Xenografts and Associated with Glioblastoma Subtypes. Stem Cell Reports. 2015;5:1-9 pubmed publisher
    ..This study proposes a different framework for the study and use of BTIC lines and provides precursor biology insights into GBM. ..